With the early termination of the applicable waiting period under the HSR Act, the collaboration agreement with Mylan is effective as of
Additional details regarding the collaboration can be found in Momenta's Form 8-K filed with the
Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.
To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.
Our logo, trademarks, and service marks are the property of
MOMENTA INVESTOR CONTACT:
Sarah Carmody Momenta Pharmaceuticals1-617-395-5189 IR@momentapharma.com MOMENTA MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications1-781-235-3060 Momenta@macbiocom.com
News Provided by Acquire Media